about
Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patientsAltered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementiaStudies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins.Proteome studies of CSF in AD patients.The future of blood-based biomarkers for Alzheimer's disease.Secular changes in cognitive predictors of dementia and mortality in 70-year-olds.Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidenceDeveloping novel blood-based biomarkers for Alzheimer's diseaseAdvances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds.Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implicationsThe Goteborg MCI study: mild cognitive impairment is a heterogeneous conditionCSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.The use of proteomics in biomarker discovery in neurodegenerative diseases.The link between cholesterol and Alzheimer's disease.Frontotemporal dementia--a brief review.Cholesterol and Alzheimer's disease--is there a relation?Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial.The pattern of cognitive symptoms predicts time to dementia onset.Small heat shock proteins Hsp27 or alphaB-crystallin and the protein components of neurofibrillary tangles: tau and neurofilaments.Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease.Both total and phosphorylated tau are increased in Alzheimer's disease.A new rating scale for age-related white matter changes applicable to MRI and CT.Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity.Treatment of Alzheimer's disease with clioquinol.[A new putative principle for diagnosis of Creutzfeldt-Jakob disease].Biological correlates of clinical subgroups of Alzheimer's disease.Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness.Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein.Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients.Prediction of mild cognitive impairment that evolves into Alzheimer's disease dementia within two years using a gene expression signature in blood: a pilot study.HPA axis activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment-refractory depression.Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.High total cholesterol levels in late life associated with a reduced risk of dementia.Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.
P50
Q24804838-B6ADDF4C-F1D5-45F7-9610-81742E7315E7Q28245852-F9992A8B-9BC2-43A6-B2F2-F18466913033Q30881660-B650EDCD-1BD7-4E97-97A4-FFEF1A948142Q33227405-55F84E52-DAFF-43EC-84F7-0EC709D49EF5Q34026317-EDBD37DF-6168-42A2-90CB-2C575FA0D024Q34125528-76559B84-979F-483C-9B0F-9F518D2D1C43Q34235541-15A0BAC0-781A-4A8D-8CD3-5D97D18ECCD2Q34394080-A32C7AC1-6C20-462D-91DC-BE3C101C58F4Q35134373-BB59BC5A-B93F-4B27-BB5C-560FE45FD15FQ35474448-C595A26A-EAA9-4693-B480-C48AA7523B39Q35482194-77CCB0BD-D47A-42A4-B22A-FADA97A6CFBAQ35484657-89916BCB-1B43-4F40-831D-8A38D717E501Q35580179-58ADBD0D-7AA6-4156-9B9B-15E45EC0244DQ35899066-A21BCFA6-5459-4832-8B6D-9BEB165066B4Q36141398-C0874A65-9797-4937-AABC-307AEB717498Q36255194-D0C95DA4-B1D6-4CDB-AFD1-AB89E6FDE7C3Q36331968-4AAFF566-0B6A-4E91-AC3B-5EA494D8DDFCQ36332900-5AB40B9D-6CA3-43BA-85D5-BF53DDD180DEQ37293025-04E38BB1-B5E4-4CA8-AB9A-2C7418F907BAQ38475082-70D74625-277D-4C12-8E4E-AA603A740F50Q39988110-AA9EB02C-3186-4C34-9170-AACB02398F44Q40038862-2628BB79-0F41-4931-BD0D-043C7F8E4A72Q40662936-1F57BA99-52FC-4D0F-BB38-67E67048B07BQ41765446-3830F001-A73B-4EBD-8DA4-EFB331F00BF4Q42505285-2946971C-C84E-4FF5-9141-9198F7EE1C3FQ42629825-853EC870-16BA-4047-8641-E3C68A1BBF13Q42651492-ABE95EB8-3F00-42DF-95AA-4BB08F0B864EQ43689212-AA789D86-EE5C-4B83-B7F3-4BEAD5827C31Q43758855-69E669A9-9DD3-4077-8CBD-63474FED2A55Q43764762-275C2B70-9B2C-48FA-A54A-469B9B68B04FQ44045244-9C3413C6-2627-4940-B252-C1D5F9E33F93Q44201890-1DDECA1C-7F9F-4D16-BBEE-B1312A9C1898Q44410838-EA67810E-3636-44BE-9C64-CB2E0CADE7DDQ44417421-3648320D-D7CF-4F03-A6DE-346B8ED83CB0Q44574707-0A6098C6-855E-4DCE-98EE-5BD4991A7A33Q44945379-9301A641-EF72-4B0B-AA38-C56BBC5E0E89Q45147415-956B0E26-4E31-4476-9F10-5C1406C6B5E3Q46120183-B51D14E5-7992-483A-A563-68B49E73B3D0Q46505847-A200A383-0FB5-4599-806C-58E105A1AF39Q46742907-FC762339-6BD1-473D-8FF2-9A7B66370CCA
P50
description
Zweeds onderzoeker
@nl
researcher ORCID ID = 0000-0003-2060-1914
@en
svensk forsker
@nb
name
Magnus Sjogren
@ast
Magnus Sjogren
@es
Magnus Sjogren
@nl
Magnus Sjogren
@sl
Magnus Sjögren
@da
Magnus Sjögren
@de
Magnus Sjögren
@en
Magnus Sjögren
@fr
Magnus Sjögren
@nb
Magnus Sjögren
@nn
type
label
Magnus Sjogren
@ast
Magnus Sjogren
@es
Magnus Sjogren
@nl
Magnus Sjogren
@sl
Magnus Sjögren
@da
Magnus Sjögren
@de
Magnus Sjögren
@en
Magnus Sjögren
@fr
Magnus Sjögren
@nb
Magnus Sjögren
@nn
prefLabel
Magnus Sjogren
@ast
Magnus Sjogren
@es
Magnus Sjogren
@nl
Magnus Sjogren
@sl
Magnus Sjögren
@da
Magnus Sjögren
@de
Magnus Sjögren
@en
Magnus Sjögren
@fr
Magnus Sjögren
@nb
Magnus Sjögren
@nn
P106
P1153
7005760078
P21
P27
P31
P496
0000-0003-2060-1914